New CAR-T cell method may allow some cancer patients to skip chemotherapy
A modified CAR-T cell therapy may spare blood cancer patients from toxic chemotherapy, according to an early-stage trial. The therapy used T memory stem cells that can renew themselves and last for years, achieving a 45% complete response rate.
A modified CAR-T cell therapy has shown promise in sparing blood cancer patients from toxic chemotherapy. The therapy used T memory stem cells that can renew themselves and last for years. In a Phase 1 trial, patients with various blood cancers received either the modified T memory stem cells or standard CAR-T cell infusions. The T memory stem cell group achieved a 45% complete response rate, compared to 10% in the standard cohort. The modified cells multiplied faster and functioned longer than standard CAR-T cells. Patients in the T memory stem cell group also had lower rates of a potentially serious inflammatory reaction.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.